ZBIO - Company ID 0001953926
The table below shows Zenas BioPharma, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $0.00 | $0.00 | $10.00M | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $60.44M | $34.40M | $43.03M | $34.91M | $33.53M | $33.81M |
Zenas BioPharma, Inc. reported annual revenue of $10.00M for fiscal year 2025. That is up 100.0% from $5.00M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $16.91M |
| $13.18M |
| $12.14M |
| $12.41M |
| $7.45M |
| $5.89M |
| Operating income | -$77.35M | -$52.58M | -$55.16M | -$37.33M | -$40.98M | -$39.70M |
| Income tax | - | - | $20.00K | -$205.00K | - | - |
| Net income | -$80.99M | -$51.50M | -$52.22M | -$33.57M | -$38.61M | -$37.98M |
| EPS (diluted) | -$1.46 | -$1.22 | -$1.25 | -$0.80 | -$5.02 | -$24.23 |